Skip to main content
Skip to main content
BEUT logo

Science to Consumers, Inc. (BEUT)

$0.00 +$0.00 (+0.00%) |HOLD · 48 · C
MCap: 3K| Vol: 1.0K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Science to Consumers, Inc. (BEUT) trades at $0.00 with AI Score 48/100 (Grade C). Science to Consumers, Inc. is a development stage company focused on marketing anti-aging cream and distributing Argan oil products. Market cap: $3,192, Sector: Consumer defensive.

Last analyzed: Mar 17, 2026
Science to Consumers, Inc. is a development stage company focused on marketing anti-aging cream and distributing Argan oil products. The company targets individual and commercial customers, including spas and stores.

Analyst Coverage for BEUT: BEUT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BEUT against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Council Score · Weighted Average of 3 Disciplines
HOLD 48/100 · C

BEUT: the 1 perspectives are evenly split.

Council Score · 8 perspectives · See tabs for details →

Science to Consumers, Inc. (BEUT) Consumer Business Overview

CEOEnsley Edwon Lam
Employees1
HeadquartersGuangzhou, CN
IPO Year2014

Science to Consumers, Inc., operating in the consumer defensive sector, is a development stage company focused on marketing anti-aging cream under the DermaLastyl name and distributing Argan oil. Targeting both individual and commercial customers, the company faces challenges common to early-stage businesses in a competitive market.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 17, 2026

What Is the Investment Thesis for BEUT?

Science to Consumers, Inc. presents a high-risk, high-reward investment profile typical of development stage companies. With a market capitalization of $0.00B and a negative P/E ratio of -0.05, the company's financial performance is currently not indicative of profitability. Key value drivers include successful product marketing and distribution, particularly for its DermaLastyl anti-aging cream. Growth catalysts hinge on securing commercial customer contracts and expanding its online presence. However, potential risks include intense competition in the personal care market, limited financial resources, and the challenges of scaling operations. Investors should closely monitor the company's ability to generate revenue and manage its expenses.

Based on FMP financials and quantitative analysis

BEUT Key Highlights

  • Market capitalization of $0.00B indicates a micro-cap company with limited resources.
  • P/E ratio of -0.05 reflects the company's current lack of profitability.
  • Beta of 0.11 suggests the stock is less volatile than the overall market.
  • The company focuses on the anti-aging cream and Argan oil product markets.
  • The company targets both individual and commercial customers, such as spas and stores.

Who Are BEUT's Competitors?

BEUT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
FACYF Fancl Corporation $17.45 +0.00% $2.37B 63
SGI Somnigroup International Inc $72.67 +0.48% $15.28B 62
ELF e.l.f. Beauty, Inc. $61.15 +0.77% 4B 59
MIOFF Milbon Co., Ltd. $52.60 +0.00% $1.71B 58
KCDMF Kimberly-Clark de México, S. A. B. de C. V. $2.10 -3.67% $6.30B 48
KCDMY Kimberly-Clark de México, S. A. B. de C. V. $10.66 +4.00% $6.41B 48
PG The Procter & Gamble Company $149.61 +0.86% $348.38B 48
RAY Raytech Holding Limited Ordinary Shares (RAY) $3.13 -0.16% $9.30M 48

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BEUT's Key Strengths?

  • Proprietary DermaLastyl anti-aging cream formulation.
  • Targeting both individual and commercial customers.
  • Distribution of Argan oil products.
  • Focus on a growing anti-aging market.

What Are BEUT's Weaknesses?

  • Development stage company with limited resources.
  • Dependence on a small product line.
  • Limited brand recognition.
  • Single employee.

What Could Drive BEUT Stock Higher?

  • Launch of new marketing campaigns to promote DermaLastyl cream.
  • Potential partnerships with spas and salons for product distribution.
  • Expansion of online sales channels through e-commerce platforms.
  • Development of new skincare products to complement existing offerings.
  • Exploration of international market opportunities for product expansion.

What Are the Key Risks for BEUT?

  • Intense competition from established players in the personal care market.
  • Limited financial resources to support marketing and product development.
  • Changing consumer preferences and trends in the skincare industry.
  • Dependence on a small product line and limited customer base.
  • Regulatory compliance and potential legal challenges.

What Are the Growth Opportunities for BEUT?

  • Expansion into E-commerce Channels: Science to Consumers, Inc. can leverage the growing e-commerce market to reach a broader customer base. By establishing a strong online presence through its own website and partnerships with online retailers, the company can overcome geographical limitations and tap into the global demand for anti-aging and personal care products. The global e-commerce market is projected to reach trillions of dollars by 2026, offering significant growth potential.
  • Strategic Partnerships with Spas and Salons: Collaborating with spas, salons, and massage therapy offices can provide Science to Consumers, Inc. with a valuable distribution channel and enhance brand visibility. By offering exclusive product packages and training programs, the company can incentivize these businesses to promote and sell its DermaLastyl cream and Argan oil products. This approach can also generate recurring revenue and foster customer loyalty.
  • Product Line Expansion: Science to Consumers, Inc. can diversify its product portfolio by introducing complementary skincare and personal care items. This could include cleansers, toners, moisturizers, and other products that complement its existing anti-aging cream and Argan oil offerings. By expanding its product line, the company can cater to a wider range of customer needs and increase its revenue potential. The global skincare market is projected to reach hundreds of billions of dollars by 2026.
  • Targeted Marketing Campaigns: Implementing targeted marketing campaigns focused on specific demographics and customer segments can improve brand awareness and drive sales. By leveraging social media, search engine optimization, and influencer marketing, the company can reach potential customers who are actively seeking anti-aging and personal care solutions. Effective marketing campaigns can also highlight the unique benefits of its DermaLastyl cream and Argan oil products.
  • International Market Expansion: Science to Consumers, Inc. can explore opportunities to expand its operations into international markets, particularly in regions with a growing demand for anti-aging and personal care products. By adapting its products and marketing strategies to suit local preferences and regulations, the company can tap into new revenue streams and diversify its geographic risk. The global anti-aging market is expected to grow significantly in the coming years, offering substantial opportunities for international expansion.

What Opportunities Does BEUT Have?

  • Expansion into e-commerce channels.
  • Strategic partnerships with spas and salons.
  • Product line expansion with complementary skincare items.
  • International market expansion.

What Threats Does BEUT Face?

  • Intense competition in the personal care market.
  • Changing consumer preferences and trends.
  • Regulatory requirements and compliance.
  • Economic downturn affecting consumer spending.

What Are BEUT's Competitive Advantages?

  • Proprietary DermaLastyl anti-aging cream formulation.
  • Established distribution channels with spas and stores.
  • Brand recognition in the anti-aging skincare market.
  • First-mover advantage in specific niche markets.

What Does BEUT Do?

Science to Consumers, Inc., founded in 2013 and based in Guangzhou, China, is a development stage company operating within the household and personal products industry. Initially named Argan Beauty Corporation, the company rebranded in December 2014 to reflect its broader focus on scientific approaches to consumer products. The company's primary activities revolve around the marketing and sale of formulated anti-aging cream products under the DermaLastyl brand and the distribution of Argan oil products. Science to Consumers, Inc. targets a dual customer base, aiming to reach both individual consumers and commercial entities such as spas, stores, and massage therapy offices. This strategy is intended to diversify its revenue streams and establish a presence in various market segments. As a development stage company, Science to Consumers, Inc. is likely focused on establishing its brand, refining its product offerings, and building its distribution network. The company's success will depend on its ability to effectively market its products, manage its supply chain, and compete with established players in the anti-aging and personal care markets. The company currently has one employee.

What Products and Services Does BEUT Offer?

  • Markets and sells anti-aging cream products under the DermaLastyl name.
  • Distributes Argan oil products.
  • Targets individual customers seeking anti-aging solutions.
  • Aims to sell to commercial customers like spas and stores.
  • Focuses on formulating and distributing skincare products.
  • Operates as a development stage company.

How Does BEUT Make Money?

  • Sells anti-aging cream products directly to consumers.
  • Distributes Argan oil through various channels.
  • Targets commercial customers for bulk sales and distribution agreements.

What Industry Does BEUT Operate In?

Science to Consumers, Inc. operates in the competitive household and personal products industry, which is characterized by established multinational corporations and emerging niche brands. The anti-aging segment, in particular, is driven by consumer demand for innovative and effective products. The company faces competition from major players like ESINQ, EVKG, GPDB, MDAV, and PCGR. Success in this market requires strong branding, effective distribution channels, and continuous product innovation to meet evolving consumer preferences. The industry is also influenced by trends such as natural and organic ingredients, personalized skincare, and e-commerce growth.

Who Are BEUT's Key Customers?

  • Individual consumers seeking anti-aging skincare solutions.
  • Spas and salons offering skincare treatments.
  • Retail stores selling personal care products.
  • Massage therapy offices using Argan oil.
AI Confidence: 71% Updated: Mar 17, 2026

BEUT Financials

Fundamental Snapshot

Return on Equity (TTM)
+196.2%
Current Ratio
0.1

Based on FMP financials and quantitative analysis

Bull Case vs Bear Case

Bull Case

  • Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the growth potential.
  • Community sentiment has shifted positively, with discussions highlighting the innovative products and services that resonate with consumers.
  • Increased media coverage has spotlighted the company's unique approach to consumer science, generating buzz and interest among potential investors.
  • Recent partnerships with key industry players have strengthened its market position, suggesting a robust growth trajectory.

Bear Case

  • Concerns about operational scalability have emerged, with some community members questioning whether the company can meet growing demand effectively.
  • Negative sentiment surrounding recent product recalls has raised doubts about quality control, impacting public perception.
  • Competitive pressures are mounting as new entrants in the consumer science space are gaining traction, potentially eroding market share.
  • Some analysts express skepticism regarding the sustainability of the current growth rate, pointing to potential market saturation risks.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

BEUT Latest News

No recent news available for BEUT.

BEUT Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BEUT.

Price Targets

Wall Street price target analysis for BEUT.

BEUT MoonshotScore

48/100

What does this score mean?

The MoonshotScore rates BEUT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Ensley Edwon Lam

CEO

Ensley Edwon Lam serves as the CEO of Science to Consumers, Inc. Details regarding Lam's prior experience and educational background are not available. As the company manages a single employee, Lam's role likely encompasses a wide range of responsibilities, from strategic planning and product development to marketing and sales. Lam's leadership is critical to the company's success, given its early stage and limited resources.

Track Record: Given the company's development stage and limited information available, it is difficult to assess Ensley Edwon Lam's track record. Key milestones under Lam's leadership would include securing initial funding, developing the DermaLastyl anti-aging cream formulation, establishing distribution channels, and generating revenue. The company's future performance will depend heavily on Lam's ability to execute its business plan and navigate the challenges of a competitive market.

BEUT OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Liquidity for stocks trading on the OTC Other tier is typically very low, with wide bid-ask spreads and limited trading volume. This can make it difficult for investors to buy or sell shares without significantly impacting the price. The lack of liquidity also increases the risk of price manipulation and makes it challenging to establish a fair market value for the stock. Investors should exercise extreme caution when trading stocks on the OTC Other tier due to the inherent liquidity risks.
OTC Risk Factors:
  • Limited or no financial disclosure.
  • Low trading volume and liquidity.
  • Higher risk of fraud and manipulation.
  • Lack of regulatory oversight.
  • Potential for delisting and loss of investment.
Due Diligence Checklist:
  • Verify the company's registration and legal status.
  • Review any available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team and their experience.
  • Check for any regulatory actions or legal issues.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before investing.
Legitimacy Signals:
  • Company registration and legal compliance.
  • Availability of some financial information, even if limited.
  • Active website and communication channels.
  • Positive customer reviews or testimonials (if available).
  • Industry partnerships or affiliations (if any).

Common Questions About BEUT (Consumer Defensive)

What does Science to Consumers, Inc. do?

Science to Consumers, Inc. is a development stage company that focuses on the formulation, marketing, and sale of anti-aging cream products under the DermaLastyl brand, as well as the distribution of Argan oil. The company targets both individual consumers seeking skincare solutions and commercial customers like spas, salons, and retail stores. Operating in the consumer defensive sector, Science to Consumers, Inc. aims to establish a presence in the competitive household and personal products market by offering specialized skincare products.

What do analysts say about BEUT stock?

As a development stage company trading on the OTC market, Science to Consumers, Inc. (BEUT) currently lacks analyst coverage. Key valuation metrics such as revenue growth, profitability, and cash flow are limited or unavailable. Investors should conduct their own thorough due diligence and consider the risks associated with investing in micro-cap companies with limited financial disclosure. The company's future performance will depend on its ability to execute its business plan and generate revenue.

What are the main risks for BEUT?

Science to Consumers, Inc. faces several key risks, including intense competition in the personal care market, limited financial resources, and dependence on a small product line. As a development stage company, it also faces execution risks related to product development, marketing, and distribution. The company's OTC listing adds further risks related to liquidity, transparency, and regulatory oversight. Investors should carefully consider these risks before investing in BEUT.

What are the key factors to evaluate for BEUT?

Science to Consumers, Inc. (BEUT) holds an AI score of 48/100 (low). Not financial advice.

How frequently does BEUT data refresh on this page?

BEUT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven BEUT's recent stock price performance?

Science to Consumers, Inc. (BEUT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary DermaLastyl anti-aging cream formulation. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BEUT overvalued or undervalued right now?

Valuing Science to Consumers, Inc. (BEUT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying BEUT?

Before investing in Science to Consumers, Inc. (BEUT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available on the company's financials and operations.
  • OTC market carries higher risks than major exchanges.
Data Sources

Popular Stocks